Health experts are alarmed as Republicans degrade the country’s pivotal HIV programs — and break promises made during Trump’s ...
Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
Art is dedicated to bringing action and awareness to the AIDS crisis. New Mexico State University’s Art Museum (UAM) and ...
Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...
Either we get ahead of this crisis or watch a generation of Americans be swept into the devastating grip of disease.
The new funding will enable QSimulate to scale operations and accelerate the expansion of its platform to meet demand in collaborations with multinational companies that include Google, Mitsui, JT ...
Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...
A daily pill that is cheaper and easier to take than currently available weight loss drugs helps people lose around a tenth ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...
WHO emphasizes integrating surveillance into national STI programs. Zoliflodacin, a novel antimicrobial agent, shows promise in treating gonorrhea, demonstrating non-inferiority to ...
Zacks Investment Research on MSN
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
Merck MRK announced positive top-line results from a pivotal late-stage study evaluating its investigational, once-daily, ...
WHO warns that if resistance continues to increase, gonorrhoea could become extremely difficult—or even impossible—to treat using existing medications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback